Who Can Participate?
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients with Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-V11
Principal Investigator
Annick
Desjardins
Protocol Number
PRO00110119
NCT ID
NCT05734560
Phase
I
Enrollment Status
Open to Enrollment